Literature DB >> 35687189

URCHOICE: Preferences for Pre-Exposure Prophylaxis (PrEP) Options for HIV Prevention Among Kenyan men who have sex with men and Transgender Women in Nairobi, Kisumu and the Coast.

Robert C Bailey1,2, Makobu Kimani3, Rhoda Kabuti4, Edwin Gumbe5, George Otieno6, Joshua Kimani4, Duncan Okall5, Eduard J Sanders3,7,8, Fredrick O Otieno5.   

Abstract

HIV prevention method preferences were evaluated among Kenyan men who have sex with men (MSM) and transgender women (TW) from three sites: Kisumu, Nairobi and the Coast. Information sessions detailing the attributes, duration of protection, route of administration and probable visibility were attended by 464 HIV negative participants, of whom 423 (median age: 24 years) agreed to be interviewed. Across pairwise comparisons daily PrEP was by far the least preferred (1%); quarterly injections (26%) and monthly pills (23%) were most preferred, followed by yearly implant (19%) and condoms (12%). When participants were "forced" to choose their most preferred PrEP option, only 10 (2.4%) chose the daily pill; more (37.1%) chose the quarterly injection than the monthly pill (34.8%) and the yearly implant (25.8%). TW preferred the yearly implant over the quarterly injection. To achieve the rates of PrEP uptake and adherence necessary for protecting large proportions of vulnerable MSM and TW, a variety of long-acting products should be developed and made accessible to appeal to a diversity of preferences.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HIV; Implants; Injectables; Long-acting PrEP; Men who have sex with men; Pre-exposure Prophylaxis; Transgender Women

Year:  2022        PMID: 35687189     DOI: 10.1007/s10461-022-03741-2

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  1 in total

Review 1.  PrEP Product Acceptability and Dual Process Decision-Making Among Men Who Have Sex with Men.

Authors:  José A Bauermeister; Julie S Downs; Douglas S Krakower
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.